Olajubutu Oluwabukunmi, Ogundipe Omotola D, Adebayo Amusa, Adesina Simeon K
Department of Pharmaceutical Sciences, Howard University, Washington, DC 20059, USA.
Pharmaceutics. 2023 Apr 22;15(5):1318. doi: 10.3390/pharmaceutics15051318.
Pancreatic cancer is fast becoming a global menace and it is projected to be the second leading cause of cancer-related death by 2030. Pancreatic adenocarcinomas, which develop in the pancreas' exocrine region, are the predominant type of pancreatic cancer, representing about 95% of total pancreatic tumors. The malignancy progresses asymptomatically, making early diagnosis difficult. It is characterized by excessive production of fibrotic stroma known as desmoplasia, which aids tumor growth and metastatic spread by remodeling the extracellular matrix and releasing tumor growth factors. For decades, immense efforts have been harnessed toward developing more effective drug delivery systems for pancreatic cancer treatment leveraging nanotechnology, immunotherapy, drug conjugates, and combinations of these approaches. However, despite the reported preclinical success of these approaches, no substantial progress has been made clinically and the prognosis for pancreatic cancer is worsening. This review provides insights into challenges associated with the delivery of therapeutics for pancreatic cancer treatment and discusses drug delivery strategies to minimize adverse effects associated with current chemotherapy options and to improve the efficiency of drug treatment.
胰腺癌正迅速成为一种全球威胁，预计到2030年将成为癌症相关死亡的第二大主要原因。胰腺腺癌发生在胰腺的外分泌区域，是胰腺癌的主要类型，约占胰腺肿瘤总数的95%。这种恶性肿瘤在无症状的情况下进展，使得早期诊断困难。其特征是产生过多的称为促结缔组织增生的纤维化基质，它通过重塑细胞外基质和释放肿瘤生长因子来促进肿瘤生长和转移扩散。几十年来，人们利用纳米技术、免疫疗法、药物偶联物以及这些方法的组合，为胰腺癌治疗开发更有效的药物递送系统付出了巨大努力。然而，尽管这些方法在临床前取得了报道的成功，但在临床上并没有取得实质性进展，胰腺癌的预后正在恶化。这篇综述深入探讨了胰腺癌治疗药物递送相关的挑战，并讨论了药物递送策略，以尽量减少与当前化疗方案相关的不良反应，并提高药物治疗的效率。
